Nathan J. Dowden - Jul 1, 2022 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role
Chief Operating Officer
Signature
/s/ Jared Cohen, as Attorney-in-Fact
Stock symbol
TRDA
Transactions as of
Jul 1, 2022
Transactions value $
$0
Form type
4
Date filed
7/6/2022, 04:18 PM
Previous filing
Jun 29, 2022
Next filing
Sep 6, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRDA Stock Option (Right to Buy) Award $0 +33.8K $0.00 33.8K Jul 1, 2022 Common stock 33.8K $12.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the option shares shall vest and become exercisable on July 1, 2023, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on July 1, 2026.